What Arabio does

Arabio (legal name: Arab Company for Pharmaceutical Products) is a Saudi Arabian biopharmaceutical company founded in 2005 and headquartered in Riyadh, with a 10,000 m² cGMP-compliant manufacturing facility in Makkah Industrial Zone that has been operational since 2011. It is the first biotech manufacturing site in the GCC region purpose-built for vaccines, producing 10 vaccines that form part of Saudi Arabia's mandatory Expanded Program on Immunization (EPI), including hexavalent (HEXAXIM), pentavalent (PENTAXIM, ARAPENTA), meningococcal conjugate (MENACTRA), quadrivalent influenza (VAXIGRIPTETRA), hepatitis B (EUVAX), and tetanus/diphtheria (STABLIX, TEDALIX) products. The company also toll-manufactures biologics such as AbbVie's Humira and Janssen's biological products, and distributes a broader portfolio including COVID-19, pneumococcal, MMR, RSV, varicella, rotavirus, HPV, and MMRV vaccines.

Arabio makes money primarily through two B2B/B2G channels: (1) sale and supply of locally manufactured and licensed vaccines to government health ministries (notably the Saudi MoH for the EPI schedule, GCC health ministries via GSK partnerships, and the Saudi MoD for adult vaccination) and to private healthcare providers across MENA, and (2) contract/toll manufacturing fees and licensing royalties from global pharmaceutical partners including Sanofi, GSK, Novartis, AbbVie, Janssen, BioFarma, and InterVax. The company is majority owned (65.21%) by Tamer Group, with other Saudi shareholders including ReAya Holding International and Khalid Juffali Co Ltd, and operates with a headcount of 101–250 employees across offices in Riyadh, Makkah, and Dubai (via Alphamed).

In 2024, Arabio signed two strategically significant MOUs: a tripartite agreement with Lifera (PIF-owned) and Sanofi to locally manufacture seven mandatory-schedule vaccines with regional export potential, and an MoU with the Saudi Ministry of Defense to establish a Center of Excellence in Vaccines and an Adult Vaccination Program. Its go-to-market combines direct sales to government and healthcare provider accounts with regional distribution through Tamer Group's MENA network and dedicated distributors such as Alphamed in the UAE, supported by validated cold-chain logistics.

Name

Arabio

Legal name

Arab Company for Pharmaceutical Products

Website

https://arabio.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Arabio is a Saudi biopharmaceutical company and the first vaccine manufacturer in the GCC, operating a 10,000 m² cGMP facility in Makkah. It supplies 10 vaccines on Saudi Arabia's mandatory immunization schedule, toll-manufactures biologics for global pharma partners, and distributes across 22 MENA countries via Tamer Group.

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Manufacturing & Fill-Finish (HLAIAEAJ)

akta.pro secondary industries

Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Vaccine Cold Chain, Storage & Distribution (HLAIAEAK)

Keywords

• Vaccine manufacturing
• Biopharmaceutical products
• Biological products
• Contract manufacturing
• Cold chain distribution

Headquarters

HQ city

Riyadh

HQ country

Saudi Arabia

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Vaccine Manufacturing and Supply: Arabio manufactures and supplies vaccines to the Saudi market and MENA region through partnerships with global pharmaceutical companies. Revenue comes from contract manufacturing fees and product sales of vaccines including HEXAXIM, MENACTRA, VAXIGRIPTETRA, PENTAXIM, and others that are part of the mandatory immunization schedule.
2. Distribution and Commercialization: Partnership with Sanofi for local manufacturing where Lifera acts as contract manufacturer to Sanofi. Arabio and Tamer Group leverage local and regional distribution strength to supply vaccines and pharmaceutical products to the Saudi market.
3. Toll Manufacturing: Arabio acts as toll manufacturer for biological products, including AbbVie's Humira and other drugs, and Janssen's biological products, where the partner provides the product and Arabio handles local manufacturing.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

Arabio manufactures and supplies human vaccines and biological products from its 10,000 m2 cGMP-compliant facility in Makkah, Saudi Arabia. The company supplies 10 vaccines that are part of the mandatory Expanded Program on Immunization (EPI) in Saudi Arabia and operates as a contract/toll manufacturer for global pharmaceutical partners including Sanofi, GSK, Novartis, AbbVie, and Janssen.

Product overview

Arabio is a biopharmaceutical company specializing in human vaccines and biological products. The company operates as a contract manufacturer and distributor, providing 10 vaccines that form part of the mandatory vaccination schedule (EPI) in Saudi Arabia. The product portfolio includes hexavalent vaccines (HEXAXIM), pentavalent vaccines (PENTAXIM, ARAPENTA), meningococcal conjugate vaccines (MENACTRA), quadrivalent influenza vaccines (VAXIGRIPTETRA), hepatitis B vaccines (EUVAX 10/20 MCG), tetanus vaccines (STABLIX, TEDALIX), and various other vaccines including COVID-19, pneumococcal, MMR, RSV, varicella, rota, and HPV vaccines. Arabio also manufactures biological products including Humira under toll manufacturing agreements. The company supplies vaccines across the MENA region through partnerships with global pharmaceutical companies including Sanofi, GSK Vaccines, Novartis, Janssen, and BioFarma, with distribution through Alphamed in the UAE.

Differentiator

Problem solved

Functional benefit

Products and services

• HEXAXIM Hexavalent vaccine combining pertussis (2-component), inactivated poliomyelitis and hepatitis B vaccine (adsorbed), and Haemophilus influenzae type b conjugate vaccine (Tetanus Toxoid Conjugate). Used in pediatric mandatory immunization programs in Saudi Arabia.
• MENACTRA Quadrivalent meningococcal conjugate vaccine (MCV4) providing protection against Groups A, C, Y and W strains, conjugated with diphtheria toxoid. Used in mandatory immunization programs.
• VAXIGRIPTETRA Inactivated quadrivalent influenza vaccine (QIV) containing two A-strains (A/H1N1 and A/H3N2) and two B-strains (B Victoria and B Yamagata). Used in influenza prevention programs.
• PENTAXIM Pentavalent vaccine combining pertussis (2-component), inactivated poliomyelitis, and Haemophilus influenzae type b conjugate vaccine (Tetanus Toxoid Conjugate). Used in mandatory immunization programs.
• ARAPENTA Pentavalent vaccine containing diphtheria and tetanus toxoids, inactivated pertussis organisms, highly purified hepatitis B surface antigen (HBsAg), and Hib component as a bacterial subunit vaccine.
• EUVAX 10 MCG (PEDIA) Pediatric hepatitis B vaccine containing highly purified, non-infectious particles of hepatitis B surface antigen for protection against hepatitis B infection.
• EUVAX 20 MCG (ADULT) Adult hepatitis B vaccine containing highly purified, non-infectious particles of hepatitis B surface antigen for protection against hepatitis B infection.
• STABLIX Purified tetanus toxoid vaccine used for tetanus prevention and post-exposure prophylaxis for recent wounds that may have been contaminated with tetanus spores.
• TEDALIX Combined tetanus toxoid and diphtheria toxoid vaccine for adults.
• COVID-19 Vaccines Vaccines targeting COVID-19 disease prevention, distributed in MENA markets.
• Pneumococcal Vaccines Vaccines providing protection against pneumococcal disease.
• MMR Vaccines Measles, mumps, and rubella combination vaccines.
• RSV Vaccines Vaccines targeting respiratory syncytial virus (RSV).
• Varicella Vaccines Vaccines providing protection against chickenpox (varicella).
• Rota Vaccines Rotavirus vaccines for protection against rotavirus gastroenteritis.
• HPV Vaccines Human papillomavirus vaccines for prevention of HPV-related cancers.
• MMRV Vaccines Combined measles, mumps, rubella, and varicella vaccines.
• Humira Biologic medication manufactured locally under toll manufacturing agreement with AbbVie for the Saudi market.

Quantifiable outcome

• Market leader in Saudi Arabia supplying 10 vaccines part of mandatory immunization schedule
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• General Directorate of Health Services at the Ministry of Defense (Saudi Arabia)coreStrategic or Co-development Partner · 25 September 2024Arabio signed MoU with the Ministry of Defense's Health Services to establish a Center of Excellence in Vaccines. The partnership includes implementation of Adult Vaccination Program, development of new methodologies for healthcare delivery projects, training and educational courses for healthcare practitioners, and awareness programs on immunization.
• SanoficoreStrategic or Co-development Partner · 6 July 2024Arabio partnered with Sanofi and Lifera (PIF-owned biopharma company) to manufacture and supply vaccines in Saudi Arabia. Sanofi will share biotechnological expertise to initially manufacture seven vaccines part of the mandatory immunization schedule, with potential for regional export market. Lifera will be contract manufacturer to Sanofi through state-of-the-art manufacturing facilities, while Arabio leverages Tamer Group's distribution strength.
• LiferacoreStrategic or Co-development Partner · 6 July 2024Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF), partnered with Sanofi and Arabio to increase local vaccine production. Lifera will serve as contract manufacturer to Sanofi through manufacturing facilities, while collaborating with Arabio for local and regional distribution of vaccines and pharmaceutical products in Saudi Arabia.
• GSK VaccinescoreTechnology or Integration · 20 March 2014Tripartite manufacturing agreement between Arabio, GSAL and GSK Vaccines established long-term alliance. Arabio appointed as contract manufacturer for filling and packaging of selected liquid vaccines in prefilled syringes and vials for GCC countries. All GSK Vaccines for Saudi Arabia's Universal Vaccination Program are manufactured locally either by GSAL or Arabio.
• AlphamedminorChannel Partner/ Reseller/ Distributor · 10 January 2012Arabio appointed Alphamed as its sales and distribution partner in the United Arab Emirates (UAE). Alphamed handles distribution of Arabio's vaccines in the UAE market.
• Novartis Vaccines & DiagnosticscoreTechnology or Integration · 11 September 2010Novartis partnered with Arabio for Middle East vaccine production. Technical assistance from Novartis' Vaccines and Diagnostics divisions for Arabio's manufacturing facility in Makkah, with technology transfer agreement enabling manufacture of Menveo meningitis vaccine, Agrippal flu vaccine, and Quinvaxem pentavalent vaccine.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Indian Immunologicals: Indian vaccine manufacturer (Bulls Group/NDDB-affiliated) supplying pediatric and travel vaccines to emerging markets including MENA. Comparable as a regional-to-emerging market vaccine producer with similar WHO-prequalification positioning.
• Biological E: Indian vaccine and biologics manufacturer with WHO-prequalified products supplying emerging markets. Comparable as a contract manufacturer expanding into MENA with similar technology transfer models to Arabio.

Broad incumbents

• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi-listed pharmaceutical manufacturer with a diversified portfolio across generics and select biologics. Comparable as a domestic Saudi pharmaceutical peer serving similar government and institutional channels.
• Sanofi Pasteur: Global vaccines leader and Arabio's primary technology transfer partner. Comparable as a vaccine originator whose products Arabio manufactures under license, defining the competitive benchmark for capability and pipeline depth.
• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer with a broad generics and biologics portfolio. While not vaccine-specialized, Julphar is a comparable regional pharmaceutical manufacturer competing for GCC government and institutional contracts.
• Serum Institute of India: World's largest vaccine manufacturer by doses, supplying WHO-prequalified vaccines globally including MENA EPI programs. Comparable as a low-cost, high-volume vaccine producer competing on price in regional tenders.
• GSK Vaccines: Global vaccines leader with a tripartite manufacturing agreement with Arabio and GSAL. Comparable as both a partner and a benchmark global vaccine originator competing in the same MENA EPI markets.

Regional players

• BioFarma: Indonesian state-owned vaccine manufacturer and Arabio's licensing partner for WHO-prequalified vaccines in MENA. Comparable as a regional vaccine producer leveraging technology transfer partnerships for emerging market expansion.
• Vacsera (Egyptian Holding Company for Biological Products and Vaccines): Egyptian state-affiliated vaccine and biological products manufacturer and a 2.84% shareholder of Arabio. Vacsera is a comparable regional vaccine producer with overlapping MENA distribution footprint and product portfolio.

Direct peers

• Lifera: Saudi Arabia-based biopharmaceutical company wholly owned by the Public Investment Fund (PIF). Lifera is positioned as Sanofi's contract manufacturer in the 2024 trilateral MOU with Arabio, making it the most directly comparable peer in local vaccine manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/arab-company-for-pharmaceutical-products-arabio
• Xx.com/arabioofficial

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arabio